Rare ashy dermatosis‐like hyperpigmentation associated with osimertinib

Autor: Kazuhito Funai

Publikováno v: Thoracic Cancer, Vol 13, Iss 9, Pp 1436-1437 (2022)

Abstract Osimertinib, a third‐generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is the most reliable EGFR‐TKI and is widely used as the first‐line treatment for EGFR mutation‐positive non‐small cell lung ca

Externí odkaz: https://doaj.org/article/a8d117388623481a8f884cb6693b04b7

Translation and linguistic validation of the FACT-EGFRI-18 quality of life instrument from English into Dutch

Autor: Joel B. Epstein, Mario E. Lacouture, Ad A. Kaptein, Hans Gelderblom, Helen Gall, Jan Ouwerkerk, Johan W.R. Nortier, Jason M. Bredle, Natascha A.W.P. Schrama, Jan A.C. Brakenhoff, Christine B. Boers-Doets

Publikováno v: European Journal of Oncology Nursing, 17(6), 802-807
Boers-Doets, C B, Gelderblom, H, Lacouture, M E, Bredle, J M, Epstein, J B, Schrama, N A W P, Gall, H E, Ouwerkerk, J, Brakenhoff, J A C, Nortier, J W R & Kaptein, A A 2013, ' Translation and linguistic validation of the FACT-EGFRI-18 quality of life instrument from English into Dutch ', European Journal of Oncology Nursing, vol. 17, no. 6, pp. 802-807 . https://doi.org/10.1016/j.ejon.2013.03.004
European Journal of Oncology Nursing, 17(6), 802-807. Churchill Livingstone

Purpose The Functional Assessment of Cancer Therapy-Epidermal Growth Factor Receptor Inhibitor 18 (FACT-EGFRI-18) is a patient-reported outcomes questionnaire developed to assess the effect of EGFRI on patients. The FACT-EGFR-18 was translated into D

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8343e3048def41090687ef4b93f05c0
https://doi.org/10.1016/j.ejon.2013.03.004